Thomas E. Olencki
The Ohio State University Wexner Medical Center · 226 works · 11,029 citations · h-index 46
Top works
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- Kidney Cancer
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- Guidelines of care for the management of basal cell carcinoma
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
- Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
- Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
- Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
- Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
- Kidney Cancer, Version 3.2015
- Basal Cell and Squamous Cell Skin Cancers
- F-18 Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of Distant Metastases From Renal Cell Carcinoma
- Testicular Cancer
- Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
- Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor‐infiltrating lymphocytes
- The role of local therapy in the management of lung and liver oligometastases
- Testicular Cancer, Version 2.2015
- A Global Review of Melanoma Follow-up Guidelines.